Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0U7VZ
|
|||
| Former ID |
DIB010291
|
|||
| Drug Name |
TD-2749
|
|||
| Indication | Gastrointestinal disease [ICD-11: DE2Z] | Discontinued in Phase 1 | [1] | |
| Company |
Theravance
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H38N6O2
|
|||
| Canonical SMILES |
CC(C)N1C2=CC=CC=C2C(=N1)C(=O)NC3CC4CCC(C3)N4CCN5CCN(CC5)C(=O)C
|
|||
| InChI |
1S/C26H38N6O2/c1-18(2)32-24-7-5-4-6-23(24)25(28-32)26(34)27-20-16-21-8-9-22(17-20)31(21)15-12-29-10-13-30(14-11-29)19(3)33/h4-7,18,20-22H,8-17H2,1-3H3,(H,27,34)/t20?,21-,22+
|
|||
| InChIKey |
ZQMXTDPQEHZTBG-FRIKZZABSA-N
|
|||
| CAS Number |
CAS 863248-59-3
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | 5-HT 4 receptor (HTR4) | Target Info | Agonist | [2] |
| KEGG Pathway | Calcium signaling pathway | |||
| cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | ||||
| Serotonergic synapse | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| 5HT4 type receptor mediated signaling pathway | ||||
| Pathwhiz Pathway | Excitatory Neural Signalling Through 5-HTR 4 and Serotonin | |||
| Reactome | Serotonin receptors | |||
| G alpha (s) signalling events | ||||
| WikiPathways | Serotonin Receptor 4/6/7 and NR3C Signaling | |||
| Monoamine GPCRs | ||||
| GPCRs, Class A Rhodopsin-like | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800021879) | |||
| REF 2 | A Hybrid Structural Approach to Analyze Ligand Binding by the Serotonin Type 4 Receptor (5-HT4). Mol Cell Proteomics. 2013 May; 12(5): 1259-1271. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.